Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review
Case Reports in Hematology · 2026-01 · 2026 (1)
DOI: 10.1155/crh/5518867 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Hematology, online erschienen am 21.05.2026. Verfasst von Veysel Erol und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Wunderlich syndrome (WS) is a spontaneous, nontraumatic intrarenal or perirenal hemorrhage most commonly related to renal neoplasms, vascular disorders, infection, cyst rupture, or anticoagulation. Clinical severity ranges from self‐limited bleeding to hemorrhagic shock. Case We report a 58‐year‐old woman with triple‐negative myelofibrosis (MF) who was started on hydroxyurea (HU) 500 mg/day and low‐dose acetylsalicylic acid (ASA). On Day 60, she presented with bilateral perirenal and intrarenal hemorrhage confirmed by contrast‐enhanced abdominal computed tomography. ASA was discontinued and bleeding ceased spontaneously. One month later, she represented with recurrent bilateral hemorrhage without ASA exposure and marked neutrophilic leukocytosis. Concomitant purpuric skin lesions, positive antinuclear antibodies (ANA, 1:160), and low C3 levels raised suspicion for a HU‐associated vasculitic process; HU was discontinued. Coagulation parameters at the time of bleeding (INR: 1.2, aPTT: 26.4 s, fibrinogen: 348 mg/dL, and D‐dimer: 0.6 μg/mL) were not consistent with disseminated intravascular coagulation. Despite supportive management, the patient’s condition deteriorated and she died shortly thereafter. The exact cause of death could not be definitively determined.
Conclusion
To our knowledge, this is the first reported case of WS in a patient with MF receiving HU therapy. Clinicians should consider WS in HU‐treated patients presenting with acute flank pain or hematuria and evaluate for potential vasculitic features.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
- Department of Pathology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
- Department of Radiology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
- Department of Urology, Konya Karapinar State Hospital, Konya, Turkey.
ORCID-Profile: Veysel Erol, Zeki Güzel, İbrahim Ethem Akgün, Gökhan Ecer
Zitieren
APA
Erol, V., Güzel, Z., Akgün, İ. E., & Ecer, G. (2026). Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/5518867
Vancouver
Erol V, Güzel Z, Akgün İE, Ecer G. Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/5518867
BibTeX
@article{Erol2026,
author = {Erol, Veysel and Güzel, Zeki and Akgün, İbrahim Ethem and Ecer, Gökhan},
title = {Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review},
journal = {Case Reports in Hematology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crh/5518867}
}
EUVIMED